Loading stock…

ALTEOGEN Inc. (A196170) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

A196170ALTEOGEN

Revenue FY25$150M

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+87%10

Revenue, next 1Y+142%10

Revenue, next 3Y, CAGR+65%10

Revenue, next 5Y, CAGR+44%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+83%10

EPS growth, FY27E+31%9

EPS growth, FY28E+50%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 87%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 65%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 44%/yr over five years.10/10

WATCH

Revenue grew 87%/yr over the last 3 years; forecasts see it cooling to 65%/yr.

Earnings are set to grow slower than sales (EPS about 50%/yr vs revenue 65%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

A196170ALTEOGEN

Total return Current5057%

Price return Current5057%

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return+2%7

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high59%2

1-year return-27%2

3-year return+402%10

5-year return+471%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +402% over three years and +471% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

None flagged.

WEAKNESSES

It's down 27% over the past year, now 41% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-8%) and so far this year (-24%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Alteogen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

A196170ALTEOGEN

Revenue FY25$150M

GROWTH RATING↗

VERY STRONG99 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+87%10

Revenue, next 1Y+142%10

Revenue, next 3Y, CAGR+65%10

Revenue, next 5Y, CAGR+44%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+83%10

EPS growth, FY27E+31%9

EPS growth, FY28E+50%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 99% of companies worldwide.

Revenue grew 87%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 65%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 44%/yr over five years.10/10

WATCH

Revenue grew 87%/yr over the last 3 years; forecasts see it cooling to 65%/yr.

Earnings are set to grow slower than sales (EPS about 50%/yr vs revenue 65%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

A196170ALTEOGEN

Total return Current5057%

Price return Current5057%

MOMENTUM RATING↗

AVERAGE49 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return+2%7

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high59%2

1-year return-27%2

3-year return+402%10

5-year return+471%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +402% over three years and +471% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over three months (+2%).

WATCH

None flagged.

WEAKNESSES

It's down 27% over the past year, now 41% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-8%) and so far this year (-24%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Alteogen. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

ALTEOGEN Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Alteogen. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Alteogen. Get the full investment case.

Premium